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We have reported recently that the mouse
5-hydroxytryptamine(4a) (5-HT4(a)) receptor undergoes
dynamic palmitoylation (Ponimaskin, E. G., Schmidt,
M. F., Heine, M., Bickmeyer, U., and Richter, D. W. (2001)
Biochem. J. 353, 627–663). In the present study, con-
served cysteine residues 328/329 in the carboxyl termi-
nus of the 5-HT4(a) receptor were identified as potential
acylation sites. In contrast to other palmitoylated G-
protein-coupled receptors, the additional cysteine resi-
due 386 positioned close to the COOH-terminal end of
the receptor was also found to be palmitoylated. Using
pulse and pulse-chase labeling techniques, we demon-
strated that palmitoylation of individual cysteines is a
reversible process and that agonist stimulation of the
5-HT4(a) receptor independently increases the rate of
palmitate turnover for both acylation sites. Analysis of
acylation-deficient mutants revealed that non-palmitoy-
lated 5-HT4(a) receptors were indistinguishable from the
wild type in their ability to interact with Gs, to stimulate
the adenylyl cyclase activity and to activate cyclic nu-
cleotide-sensitive cation channels after agonist stimula-
tion. The most distinctive finding of the present study
was the ability of palmitoylation to modulate the ago-
nist-independent constitutive 5-HT4(a) receptor activity.
We demonstrated that mutation of the proximal palmi-
toylation site (Cys328 3 Ser/Cys329 3 Ser) significantly
increases the capacity of receptors to convert from the
inactive (R) to the active (R*) form in the absence of
agonist. In contrast, the rate of isomerization from R to
R* for the Cys386 3 Ser as well as for the triple, non-
palmitoylated mutant (Cys328 3 Ser/Cys329 3 Ser/Cys386
3Ser) was similar to that obtained for the wild type.
Covalent binding of long chain saturated fatty acids occurs
within a wide variety of cellular as well as viral polypeptides
(1–3). Two of the most common modifications involve acylation
with myristate (N-myristoylation) and palmitate (S-acylation).
Myristic acid is usually attached co-translationally to the NH2-
terminal glycine residue in an amide linkage by N-myristoyl-
transferase (4, 5). Palmitic acid is attached to cysteine residues
via a labile thioester bond (6). In contrast to myristate, which
generally remains attached to the polypeptides until protein
degradation, palmitic acid is added post-translationally and
turns over rapidly as a protein itself (7, 8).
Among the cellular palmitoylated proteins, polypeptides in-
volved in signal transduction (e.g. receptors, G-protein -sub-
units, and adenylyl cyclases) are prevalent. With the finding
that palmitoylation states of several proteins may be dynami-
cally regulated, it is now widely accepted that repeated cycles
of palmitoylation and depalmitoylation could have important
functional consequences for signaling (9–11). In G-protein-cou-
pled receptors (GPCRs),1 the functions of palmitoylation cover
the wide spectrum of their biological activities: from coupling to
G-proteins and regulated endocytosis to receptor phosphoryla-
tion and desensitization (9, 10, 12). For example, the palmitoy-
lation state of the 2-adrenergic receptor (2AR) regulates the
synergistic action of cAMP-dependent protein kinase and -ad-
renergic receptor kinase involved in receptor phosphorylation
and desensitization in response to ligand binding (13, 14). The
long term agonist stimulation of the 2-adrenergic receptor,
which promotes receptor phosphorylation, also increases recep-
tor depalmitoylation, resulting in decreased signaling through
the receptor (15). A mutation that prevents palmitoylation of
the A2-adrenergic receptor has been found to strongly inhibit
receptor down-regulation (16). For the bovine rhodopsin, abo-
lition of palmitoylation by mutagenesis impairs its all-trans-
retinal stimulatory activity, demonstrating the importance of
palmitoylation for dark adaptation (17). These findings show
that receptor acylation plays differing functional roles at dif-
ferent receptor-G-protein interfaces, suggesting that there is
no common function applicable to all GPCRs. Therefore, an
analysis of the functions of palmitoylation is necessary for each
individual receptor to understand its signaling mechanism.
Five-hydroxytryptamine (5-HT or serotonin) mediates phys-
iological functions in both the central nervous system and the
periphery of vertebrates through a large number of receptors.
With the exception of the 5-HT3 receptor, which is a cation
channel, all other 5-HT receptors belong to the GPCR family.
Among the 13 known genes coding for 5-HT GPCRs, only 3
(5-HT4, 5-HT6, and 5-HT7) are positively coupled to G-proteins
(Gs) that stimulate adenylate cyclases (18, 19). The 5-HT4
receptor is expressed in a wide variety of tissues, including
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brain, colon, urinary bladder, gastrointestinal tract, and heart
(20, 21). In the mammalian brain, the 5-HT4 receptor contrib-
utes to the control of acetylcholine and dopamine secretion,
facilitates cognitive performance and is also implicated in anx-
iety (22–24). Furthermore, the 5-HT4 receptor is thought to be
involved in various central and peripheral disorders, including
neurodegenerative diseases and atrial fibrillation (25, 26). The
wide distribution of 5-HT4 receptors is paralleled by the exist-
ence of many 5-HT4 splicing variants. Functional expression
has been reported for five COOH-terminal and one internal
splice variants in humans (27). In mouse, four 5-HT4 receptor
isoforms, 5-HT4(a), 5-HT4(b), 5-HT4(e), and 5-HT4(f), have been
cloned (28). All these variants, except the internal splice
product in humans, share the same sequence up to Leu358
followed by an unique COOH terminus. Because the COOH-
terminal tail seems to be involved in the fine tuning of the
coupling of GPCRs to G-proteins, it has been proposed that a
diversity of function can be attributed to the different splicing
variants of 5-HT4 receptor (29, 30).
Recently we have shown that the 5-HT4(a) receptor under-
goes palmitoylation. Our data also demonstrated that palmi-
toylation of the 5-HT4(a) is a reversible process and that agonist
stimulation of the receptor increases the turnover rate for
receptor-bound palmitate (31). In the present study we ex-
plored the functional role of palmitoylation/depalmitoylation in
serotonin-mediated signaling. By site-directed mutagenesis,
we identified Cys328/Cys329 as potential acylation sites in the
5-HT4(a) receptor. In contrast to most other palmitoylated
GPCRs, an additional cysteine residue Cys386 located in the
very distal portion of the COOH-terminal domain was also
identified as a palmitoylation site. Whereas the coupling with
the Gs protein, agonist-promoted cAMP production as well as
intracellular distribution of non-palmitoylated receptor mu-
tants were unaffected, our experimental data provide clear
evidence for a functional role of palmitoylation in the modula-
tion of constitutive activity on the 5-HT4(a) receptor. We dem-
onstrate that mutation of the proximal palmitoylation site
(Cys328 3 Ser/Cys329 3 Ser) significantly increases the capac-
ity of the receptor to convert from the inactive (R) to the active
(R*) form in the absence of a agonists. In contrast, the rate of
isomerization from R to R* for the Cys386 3 Ser as well as for
the triple, non-palmitoylated mutant (Cys328 3 Ser/Cys329 3
Ser/Cys386 3Ser) was similar to that obtained for the wild
type.
EXPERIMENTAL PROCEDURES
Materials—[9,10-3H]Palmitic acid (30–60 Ci/mmol) was purchased
from Hartmann Analytic GmbH (Braunschweig, Germany), Tran35S-
label (1000 Ci/mmol) from ICN (Eschwege, Germany), [35S]GTPS
(1300 Ci/mmol) from PerkinElmer Life Sciences (Ko¨ln, Germany). En-
zymes used in molecular cloning were obtained from New England
Biolabs (Frankfurt am Main, Germany). 5-Hydroxytryptamine (5-HT)
and protein A-Sepharose CL-4B beads were from Sigma (Deisenhofen,
Germany), GR113808A was a gift from GlaxoWellcome (Stevenage,
United Kingdom). BIMU8 was kindly provided by Boehringer
(Ingelheim, Germany). SB 207266 ((N-1-butyl-4-piperinylmethyl)-3,4-
dihydro-2H-[1,3]-oxazino[3,2-a]indole-10-carboxamide, hydrochloride)
was obtained from Laboratoires Fournier-Debat (Daix, France), and ML
10375 (2-(cis-3,5-dimethylpiperidino)ethyl 4-amino-5-chloro-2-me-
thoxybenzoate) was obtained from M. Langlois (CNRS-BIOCIS,
Chaˆtenay-Malabry, France). TC-100 insect cell medium, Dulbecco’s
modified Eagle’s medium (DMEM), trypsin versene, fetal calf serum
(FCS), 2 YT medium, Cellfectin®, and Lipofectin® reagents were pur-
chased from Invitrogen (Karlsruhe, Germany). TC-100 medium with-
out L-methionine and L-glutamine was from PAN Biotech GmbH
(Aidenbach, Germany). Cell culture dishes were purchased from Nunc
(Wiesbaden, Germany). Oligonucleotide primers were synthesized by
Invitrogen. AmpliTaq® DNA polymerase was from PerkinElmer Life
Sciences. The polyclonal antiserum AS9459, raised against the COOH-
terminal peptide of m5-HT4(a) receptor, has been described previously
(31).
Recombinant DNA Procedures—All basic DNA procedures were per-
formed as described by Sambrook et al. (32). The construction of recom-
binant baculovirus coding for the m5-HT4(a) receptor has been described
previously (31). For the expression in COS-7 cells, the m5-HT4(a) cDNA
was cleaved from pFastBac plasmid (Invitrogen) with XbaI and HindIII
endonucleases to yield the 1.1-kb fragment containing the entire coding
sequence. The fragment was treated with T4 DNA polymerase to create
the blunt ends and then ligated to the PmeI site in the multiple cloning
site of the pTracer-CMV2 donor plasmid (Invitrogen).
The 5-HT4(a) mutants with the substitution of serine for cysteines
328/329; 346; 386; 328/329 and 346; 328/329 and 386; and 346 and 386
were performed in pFastBac/5-HT4(a) plasmid using an oligonucleotide
containing the mutation(s) corresponding to the above substitutions by
standard PCR protocols, using the overlap extension technique. The
recombinant baculoviruses encoding for 5-HT4(a) mutants were con-
structed, purified, and amplified as described previously (33). All mu-
tants were verified by double-stranded dideoxy DNA sequencing at the
level of the final plasmid.
Metabolic Labeling and Immunoprecipitation of Sf9 Insect Cells—
Spodoptera frugiperda (Sf9) cells were grown in TC-100 medium sup-
plemented with 10% FCS and 1% penicillin/streptomycin (complete
TC-100). For expression, Sf9 cells (1.5  106) grown in 35-mm dishes
were infected with recombinant baculovirus encoding for wild type or
mutated 5-HT4(a) receptors at a multiplicity of infection (m.o.i.) of 10
plaque-forming units/cell. After 48 h, cells were labeled with Tran35S-
label (50 Ci/ml) in TC-100 medium without methionine or with
[3H]palmitic acid (300 Ci/ml) in TC-100 medium for the time periods
indicated in the figure legends. For the pulse-chase experiments, cells
were subsequently incubated in complete TC-100 medium supple-
mented with 100 M unlabeled palmitate and 50 M sodium pyruvate.
In some experiments, BIMU8 was added to the final concentrations as
indicated in figure legends. After labeling (or chase), cells were washed
once with ice-cold PBS (140 mM NaCl, 3 mM KCl, 2 mM KH2PO4, 6 mM
Na2HPO4, pH 7.4) and lysed in 600 l of NTEP buffer (0.5% Nonidet
P-40, 150 mM NaCl, 50 mM Tris-HCl, pH 7.9, 5 mM EDTA, 10 mM
iodoacetamide, 1 mM phenylmethylsulfonyl fluoride). Insoluble mate-
rial was pelleted (5 min, 20,000  g), and antibodies AS9459 were
added to the supernatant at a dilution of 1:60. After overnight agitation
at 4 °C, 30 l of protein A-Sepharose CL-4B was added, and samples
were incubated under gentle rocking for 2 h. After brief centrifugation,
the pellet was washed twice with ice-cold NTEP buffer, and the immu-
nocomplexes were released from the beads by incubation for 30 min at
37 °C in nonreducing electrophoresis sample buffer (62,5 mM Tris-HCl,
pH 6.8, containing 20% glycerol, 6% SDS, 0,002% bromphenol blue).
Radiolabeled polypeptides were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 12% acrylamide
gels and visualized by fluorography using Kodak X-Omat AR films.
Quantification of fluorograms was carried out by means of a Snap-
Scan1236 scanner and Gel-Pro Analyzer version 3.1 software. The
amount of [3H]palmitate incorporated was calculated relative to the
expression of the various proteins as indicated by its [35S]methionine/
cysteine labeling.
Assay for [35S]GTPS Binding in Membranes of Sf9 Cells—Agonist-
promoted binding of [35S]GTPS to different G-proteins induced by
stimulation of 5-HT4(a) receptors was performed according to the
method described previously (34). Briefly, membranes from Sf9 cells
expressing the 5-HT4(a) receptor wild type or acylation-deficient mu-
tants and G-protein  subunits (Gi1, Gi2, Gi3, Gq, Gs, and G12) together
with 12 subunits were resuspended in 55 l of 50 mM Tris-HCl, pH
7.4, containing 2 mM EDTA, 100 mM NaCl, 3 mM MgCl2, and 1 M GDP.
After adding [35S]GTPS (1300 Ci/mmol) to a final concentration of 30
nM, samples were incubated for 5 min at 30 °C in the absence or
presence of BIMU8. The reaction was terminated by adding 600 l of 50
mM Tris-HCl, pH 7.5, containing 20 mM MgCl2, 150 mM NaCl, 0,5%
Nonidet P-40, 200 g/ml aprotinin, 100 M GDP, and 100 M GTP for 30
min on the ice. The samples were incubated for 20 min with 150 l of a
10% suspension of Pansorbin cells (Calbiochem) preincubated with
nonimmune serum to remove nonspecific bound proteins. Samples were
agitated for 1 h at 4 °C with 5–10 l of appropriate G subunits-
directed antiserum preincubated with 100 l of 10% suspension of
protein A-Sepharose. Immunoprecipitates were washed three times and
boiled in 0.5 ml of 0.5% SDS; 4 ml of Ecolite was then added and
radioactivity measured by scintillation spectrometry.
Electrophysiology and Data Fitting—Electrophysiological measure-
ments were performed using the method described previously by Heine
et al. (35). Currents were measured in the whole cell patch-clamp mode.
Borosilicate glass pipettes were fire polished and had a final series
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resistance of 4–8 megohms. For measurements we used the discontin-
uous single-electrode voltage clamp amplifier SEC-05L from NPI Elec-
tronic (Tamm, Germany), which was connected to a computer through
an ITC-16 interface from Instrutech Corp. (Great Neck, NY). Data were
acquired and stored by Pulse-PulseFit 8.31 software from HEKA (Lam-
brecht, Germany) and data analysis was performed with Igor-WaveM-
etrics software. The temperature of the superfusing solution was sta-
bilized at 25  0.2 °C controlled with a Peltier control unit from ESF
Electronic (Go¨ttingen, Germany). Recordings were performed in TC-100
medium without FCS. In this medium it was possible to hold cells for
4–7 h. The standard pipette solution contained 110 mM potassium
gluconate, 1 mM CaCl2, 2 mM MgCl2, 2 mM Na2ATP, 0.4 mM GTP, 10 mM
HEPES, 10 mM EGTA, pH 7.25. The high Ca2-buffered pipette solu-
tion (15.31 nM free Ca2 as calculated by Patcher’s Power Tools soft-
ware (Francisco Mendez, Go¨ttingen, Germany)) allowed us to exclude
side effects of Ca2 ions on channel activation kinetics, as described by
Lu¨thi and McCormick (36). The osmolarity of the pipette solution was
20 mosmol below the osmolarity of the TC-100 medium. The 5-HT4(a)
receptor was stimulated by 0.1–10 M serotonin (5-HT) by pressure
application (PDES 2L-unit from NPI Electronic) from pipettes with a
diameter of 3–5 m.
The activation time constants () were estimated by an exponential
fitting. Statistical values were given as means  S.E.
Transfection of COS-7 Cells—The cDNA encoding for the wild type or
mutated 5-HT4(a) receptors in pTracer-CMV2 plasmid was introduced
into COS-7 cells by electroporation as described previously (37). Briefly,
cells were trypsinized, centrifuged, and resuspended in EP buffer (50
mM K2HPO4, 20 mM CH3CO2K, 20 mM KOH, 26.7 mM MgSO4, pH 7.4)
containing 25–2000 ng of receptor cDNA. The total amount of DNA was
kept constant at 15 g/transfection using pTracer vector. After 15 min
of exposure at room temperature, 300 l of cell suspension (107 cells)
were transferred to a 0.4-ml electroporation cuvette (Bio-Rad) and
pulsed using a Gene-Pulser apparatus (setting 1000 microfarads, 280
V). Afterward, cells were diluted in DMEM (106 cells/ml) containing
10% dialyzed fetal bovine serum (dFBS) and plated on 15-cm dishes or
into 12-well clusters at the desired density.
Determination of cAMP Production in Intact COS-7 Cells—Six h
after transfection, the complete medium was exchanged by DMEM
without dFBS containing 2 Ci/ml [3H]adenine to label the ATP pool.
After overnight incubation, cAMP accumulation was measured as de-
scribed previously (38).
Assay for [3H]GR 113808 Binding in Membrane of COS-7 Cells—
Membranes were prepared from transfected cells plated on 15-cm
dishes and grown for 24 h in DMEM with 10% dFBS as described
previously (39). The cells were washed twice with PBS, scraped with a
rubber policeman, harvested in PBS, and centrifuged at 4 °C (200  g
for 4 min). The pellet was resuspended in buffer containing 10 mM
HEPES, pH 7.4, 5 mM EGTA, 1 mM EDTA, and 0.32 M sucrose and
homogenized 10 times with a glass-Teflon potter at 4 °C. The homoge-
nate was centrifuged at 20,000 g for 20 min, the membrane pellet was
resuspended in 50 mM Hepes, pH 7.4 (5 mg of protein in 1 ml of
solution), and stored at 80 °C until use.
To perform radioligand binding studies with [3H]GR 113808 (specific
activity: 83 Ci/mmol), 100 l of membrane suspension prepared as
described above was diluted with 50 mM HEPES, pH 7.4 (2–20 g of
protein), containing 10 mM pargyline and 0.01% ascorbic acid. Samples
were incubated at 20 °C for 30 min with 100 l of [3H]GR 113808 and
50 l of buffer or competing drugs. For saturation analysis assays,
various concentrations of [3H]GR 113808 (0.001–1 nM) were used. For
competition binding experiments, the [3H]GR 113808 concentrations
were kept at 0.15 nM. The receptor densities were estimated using the
specific radioligand [3H]GR 113808 at a saturating concentration (0.4–
0.6 nM, Kd  0.12 nM) as described previously (38). 5-HT (0.5 M) was
used to determine nonspecific binding. Protein concentration was de-
termined using the Bio-Rad protein assay.
Immunohistochemistry—COS-7 cells were maintained as a mono-
layer culture in DMEM supplemented with 10% FCS. For the expres-
sion of the 5-HT4(a) receptor, the cells grown on coverslips were washed
once with OptiMEM without FCS and then transfected with 1 g of
plasmid DNAs using LipofectAMINE 2000. At 48 h after transfection,
cells were fixed with paraformaldehyde (3% in PBS) for 15 min and
washed three times with PBS, and unreacted paraformaldehyde was
quenched with 50 mM glycine for 15 min. Cells were permeabilized with
Triton X-100 (0.1% in PBS) and then incubated for 1 h with the first
antibody AS9459 diluted 1:200 in PBS containing 2% bovine serum
albumin. The second antibody (Fluor 594, (MoBiTec, Go¨ttingen,
Germany), diluted 1:100 in PBS containing 2% bovine serum albumin)
was adsorbed successively to the cells for 1 h. Unbound antibodies were
washed off after every step with PBS. Coverslips were finally mounted
in 90% (v/v) glycerol. Cells were monitored under a confocal microscope
(LSM510, Zeiss) at a magnification of 630 with appropriated filter sets.
Data Analysis—The dose-response curves were fitted by the equation
y  ((ymax  ymin)/1  (x/EC50)nH  ymin), where EC50 is the concentra-
tion of agonist producing a response equal to 50% of the maximum, ymax
and ymin correspond to the maximal and minimal values, and nH to the
Hill coefficient, by using Kaleidagraph software. Competition and sat-
uration experiments were analyzed by nonlinear regression using LI-
GAND software. Saturation experiments were also analyzed according
to Scatchard. Statistical significant differences were determined with
the StatView Student program (Abacus Concepts, Berkeley, CA) with
Student’s t test.
RESULTS
Identification of Potential Acylation Site(s) on 5-HT4(a)—
Given that the 5-HT4(a) receptor contains covalently bound
palmitic acid (31), we sought to identify potential acylation
site(s) by construction of a series of mutant receptors where
serine was substituted for cysteine residues at the receptor
carboxyl terminus (Fig. 1A). All substitution mutants along
with the wild type receptor were expressed in Sf9 insect cells by
the baculovirus system and labeled with either Tran35S-label
or [3H]palmitic acid followed by immunoprecipitation, SDS-
PAGE, and fluorography. Results of the [35S]Met labeling dem-
onstrated that all mutants were expressed at the levels com-
parable with those of the 5-HT4(a) wild type control (Fig. 1B),
which allows for a quantitative comparison of palmitoylation
levels in the different products. The amount of [3H]palmitate
incorporated into each of these mutants was calculated by
densitometry of fluorograms in relation to the expression level
of the various proteins as indicated by its [35S]methionine/
cysteine labeling (40).
Of the four cysteine residues at the COOH-terminal cytoplas-
mic domain of the receptor, Cys328/Cys329 are highly conserved
among GPCRs and also correspond to the site that has been
shown to be palmitoylated. However, replacement of these cys-
teine residues with serine did not completely abolish palmitoyla-
tion. Incorporation of [3H]palmitate into Cys3283 Ser/Cys3293
Ser mutant was 43.7 4.8% (n 4). Replacement of Cys346 alone
or in combination with Cys328/Cys329 did not significantly affect
the relative palmitoylation efficiency of the resulting mutants as
compared with the wild type (100% for the wt and 104 6.3% for
the Cys346 3 Ser) and Cys328 3 Ser/Cys329 3 Ser construct
(43.7 4.8% for the Cys3283 Ser/Cys3293 Ser and 38.1 3.9%
for the Cys328 3 Ser/Cys329 3 Ser/Cys346 3 Ser), respectively
(Fig. 1A). A single mutation of Cys386 located very close to the
COOH-terminal end, however, resulted in a decreased palmitoy-
lation as compared with the wild type. The relative palmitoyla-
tion value demonstrated that incorporation of [3H]palmitate into
the Cys386 3 Ser mutant was 61.5  5% (n  4). When Cys386
was mutated together with Cys346, relative palmitoylation effi-
ciency (57.4  5.6%) was similar to the Cys386 3 Ser receptor
(61.5  5%). In contrast, simultaneous substitution of Cys328/
Cys329 and Cys386 led to a complete elimination of any detectable
[3H]palmitic acid incorporation (Fig. 1B). Absence of palmitoyla-
tion on the Cys3283 Ser/Cys3293 Ser/Cys3863 Ser mutant was
also confirmed after prolonged (up to 6 weeks) gel exposure.
Thus, we conclude that Cys328/Cys329 and Cys386, but not Cys346,
are the potential palmitoylation sites of the 5-HT4(a) receptor.
Palmitoylation of Both Acylation Sites (Cys328/Cys329 and
Cys386) Is Agonist-promoted—We have demonstrated previ-
ously that palmitoylation of the 5-HT4(a) receptor is a dynamic
process and that receptor stimulation by agonists increases the
rate of palmitate turnover (31). Because palmitoylation of the
5-HT4(a) receptor occurs on two different sites (Cys
328/Cys329
and Cys386), we next studied the time course of agonist-induced
incorporation of [3H]palmitic acid into individual mutants. As
shown in Fig. 2A (control), the intensity of radiolabel incorpo-
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ration into both mutants increased steadily, reflecting basal
changes in palmitoylation. Next, the kinetics of [3H]palmitate
incorporation were studied in the presence of BIMU8, a 5-HT4
receptor-selective agonist (21). The results shown in Fig. 2A
reveal that exposure to BIMU8 significantly increased radiola-
bel incorporation into each individual mutant over the whole
labeling period. In both cases, BIMU8 induced an approximate
2-fold increase in labeling compared with controls (Fig. 2B).
Labeling with [35S]methionine done in parallel demonstrated
that exposure to the agonist did not influence the expression
level of these mutants (data not shown).
To determine whether the agonist-promoted increase in
palmitoylation results from an elevation in the stoichiometry of
acylation or reflects a faster exchange between labeled and
unlabeled palmitate, pulse-chase labeling experiments in the
presence or in the absence of BIMU8 were performed with
individual mutants. As seen in Fig. 2C, in the absence of
agonist (control), [3H]palmitate was released from mutated
receptors over time, representing basal depalmitoylation.
BIMU8 apparently promoted the release of radiolabel from
both mutants at all time points, reducing the amount of recep-
tor-bound palmitate by 50–55% of control. We interestingly
obtained quite similar rates of depalmitoylation for the
5-HT4(a) receptor wild type (31). The effect of BIMU8 was
receptor-specific because the increased release of [3H]palmitate
was effectively blocked by GR113808, high affinity 5-HT4(a)
receptor antagonist (data not shown). Parallel labeling with
[35S]methionine demonstrated that the rate of turnover for
mutants itself appeared to be unaffected by the treatment with
agonists. Taken together, these results (Fig. 2) suggest that
both acylation sites (Cys328/Cys329 and Cys386) are dynamically
palmitoylated and that agonist stimulation increases the rate
of palmitate turnover on each of them.
Effect of Cysteine(s) Replacement on the Receptor-G-protein
Coupling as Assessed by GTPS Binding—Co-expression of
receptor and G-protein in insect cells followed by measurement
of agonist-promoted binding of [35S]GTPS to the G subunit
provides a useful experimental approach for assessing the se-
lectivity of receptor-G-protein coupling [41). Using this system
we analyzed communication of the 5-HT4(a) receptor with G-
proteins belonging to the different families. Fig. 3 represents a
set of experiments in which Sf9 cell membranes containing Gi2,
Gi3, Gq, Gs, or G12 (in all cases the appropriate -subunit was
co-expressed with 12 subunits) and the 5-HT4(a) receptor
were incubated with [35S]GTPS in the presence or in the
absence of BIMU8. G subunits were subsequently immuno-
precipitated with the appropriate antibody and bound
[35S]GTPS was counted directly. As shown in Fig. 3A, no
binding occurred with i2, i3, q, and 12 subunits. In contrast,
co-expression of the 5-HT4(a) receptor with Gs resulted in the
increase of [35S]GTPS binding, even in the absence of agonist.
Activation of the receptor with agonist (BIMU8) elicited an
4-fold increase in binding when compared with control, dem-
onstrating that 5-HT4(a) receptor couples to G-proteins of the Gs
family. Omitting the receptor from the assay demonstrated
that Gs alone did not bind [
35S]GTPS (data not shown).
Having demonstrated that the 5-HT4(a) receptor communi-
cates with Gs, we next assessed the potential of Gs for coupling
to different acylation-deficient mutants of 5-HT4(a). As shown
in Fig. 3B, activation of mutated receptors with BIMU8 re-
FIG. 1. 5-HT4(a) receptor is palmitoylated on two different sites (Cys
328/Cys329 and Cys386). A, schematic view of the 5-HT4(a) mutants.
The cytoplasmic, carboxyl-terminal sequences of the 5-HT4(a) receptor, and six substitution mutants are given in a single-letter code. The amino acid
numbers for four cysteine residues are indicated. Boxed are the serine residues substituted for the corresponding cysteine residues. Numbers on
the right, mean  S.E. acylation efficiencies determined by densitometric analysis of fluorograms in relation to the expression level of the various
proteins as indicated by [35S]methionine/cysteine labeling (n  4). 5-HT4(a) wild type was used as control and the values obtained for 5-HT4(a) wild
type were set to 100%. B, 5-HT4(a) receptor wild type and different substitution mutants were expressed in Sf9 cells, labeled either with
[35S]methionine/cysteine (left panel) or [3H]palmitic acid (right panel) and subjected to immunoprecipitation, SDS-PAGE and fluorography.
Exposure time is 1 day for labeling with [35S]-methionine/cysteine and 1 week for labeling with [3H]palmitate. A representative fluorogram is
shown.
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sulted in an increase of [35S]GTPS binding, which was quite
similar to that obtained for the wild type. Next, the basal
constitutive receptor activity was analyzed for the single mu-
tants. As seen in Fig. 3B, the level of agonist-independent
binding of [35S]GTPS to Gs was significantly increased for the
Cys3283 Ser/Cys3293 Ser mutant compared with the receptor
FIG. 2. Palmitoylation of both acylation sites (C328/329S and C386S) is a dynamic process. A, Sf9 cells expressing the 5-HT4(a) receptor
mutants were incubated with [3H]palmitate in the presence of either vehicle (H2O, control) or 100 nM BIMU8 for the time periods indicated.
Receptors were immunoprecipitated, resolved by SDS-PAGE, and visualized by fluorography. A representative fluorogram is shown. A percentage
change of palmitoylation after BIMU8 stimulation versus vehicle is shown in B as an average  S.E. (n  4) for the wild type and individual
mutants. C, insect cells expressing the individual mutants were labeled with [3H]palmitate for 1 h and chased with medium containing nonlabeled
palmitate for the time periods indicated. During the chase time, cells were treated with vehicle (H2O, control) or BIMU8. Incorporation of the
radiolabel was assessed by receptor immunoprecipitation followed by SDS-PAGE and densitometry. One representative experiment (n  3) is
shown.
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wild type. In contrast, agonist-independent binding of
[35S]GTPS to Gs obtained for the Cys
386 3 Ser mutant was
quite similar to the wild type. Surprisingly, the substitution of
all palmitoylated cysteine residues with serine (Cys328 3 Ser/
Cys329 3 Ser/Cys386 3 Ser) reduced the high constitutive
activity obtained for the Cys3283 Ser/Cys3293 Ser mutant to
the wild type level. Fig. 3B also illustrates that the high basal
activity obtained for the Cys328 3 Ser/Cys329 3 Ser mutant
leads to a decrease in relative efficacy of agonist to stimulate
over basal constitutive activity. For the 5-HT4(a) receptor wild
type, we found a 5-fold increase in the binding of [35S]GTPS in
response to the agonist, whereas, for the Cys328 3 Ser/Cys329
3 Ser mutant, agonist stimulation resulted only in 2.2-fold
increase in [35S]GTPS binding. It is noteworthy that these
FIG. 3. Communication of the 5-HT4(a) receptor with different G-proteins: effect of palmitoylation. A, membranes were prepared from
Sf9 cells expressing recombinant proteins as indicated and then incubated with [35S]GTPS in the presence of either vehicle (H2O) or 100 nM
BIMU8. Immunoprecipitations were performed with appropriate antibodies directed against indicated G subunits. In B, 5-HT4(a) receptor wild
type or different mutants were expressed beside the Gs protein. Data points represent the means  S.E. from at least four independent
experiments. A statistically significant increase from values obtained without agonist for Cys3283 Ser/Cys3293 Ser mutant as compared with the
wild type basal activity is noted (*, p 	 0.05).
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values did not change significantly, when binding of
[35S]GTPS was analyzed as function of time after 5, 20, 40,
and 60 min of incubation (data not shown). These results indi-
cate that proximal (Cys328/Cys329) but not the distal (Cys386)
acylation site is selectively involved in modulation of agonist-
independent receptor activity.
Effect of Cysteine(s) Replacement on the Receptor-G-protein
Coupling as Assessed by Electrophysiological Assay—To ana-
lyze the effect of palmitoylation on the activation of down-
stream signal cascades, we established a new functional assay
using the patch-clamp technique (35). For this purpose, the
hyperpolarization- and cyclic nucleotide-sensitive cation chan-
nel from Heliothis virescens (HvCNG) (42) was co-expressed in
Sf9 cells in addition to the 5-HT4(a) receptor and Gs. The choice
of the HvCNG channel had several reasons. (i) The channel is
not activated at the resting potential of the Sf9 cells, which
ranges between 10 and 40 mV. (ii) The channel is highly
sensitive to cAMP. (iii) Use of the HvCNG activation kinetics
was independent of the channel expression level. The recorded
activation currents during a hyperpolarization to 100 mV
were fitted by a single exponential function, and the resulting
activation time constant for the channel () was used as param-
eter for the approximation of the intracellular cAMP
concentration.
As shown in Fig. 4, stimulation of wild type and mutated
5-HT4(a) receptors with 0.1 M serotonin resulted in a faster
activation of the current and in a significant decrease of the
channel’s activation time constant , demonstrating that acti-
vation of receptors is able to activate HvCNG via stimulation of
Gs and endogenous adenylyl cyclase(s). The activation kinetics
FIG. 4. Activation of the HvCNG cat-
ion channel mediated by the 5-HT4(a)
receptor wild type or by acylation-
deficient mutants. HvCNG currents
from Sf9-cells expressing the 5-HT4(a) re-
ceptor (wild type or mutants) together
with the G-protein subunits s, 1, 2 and
the HvCNG channel were recorded in the
whole-cell patch-clamp mode. Channel’s
activation time constants () were ob-
tained from exponential fits of currents
evoked via a voltage step to 100 mV at a
temperature of 25 °C, and each point
represents the activation time constant of
a 1-s-long pulse. Stimulation by 100 nM
serotonin (5-HT) induced a pronounced
decrease of the activation constants () in
all cases. Insets, voltage protocol and one
representative measurement of currents
from at least four independent experi-
ments for the wild type and Cys328 3
Ser/Cys329 3 Ser mutant in the absence
(control) or in the presence of 5-HT are
shown.
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obtained after agonist stimulation was similar for the mutants
and for the wild type. The stimulatory effect was reversible and
the current returned to the control values after wash-out of
agonist (Fig. 4). When the receptor or Gs were excluded from
the assay, channel activation by serotonin was not seen (35).
Repetitive application of the agonist to the 5-HT4(a) wild type
resulted in significantly declined responses, and even a 10-fold
elevation of the serotonin concentration (1 M) only marginally
decreased  during a second application. In contrast, repetitive
agonist stimulation of acylation-deficient mutants resulted in
the efficient channel activation (data not shown), suggesting
only low rates of agonist-promoted receptor desensitization for
the acylation-deficient mutants of the 5-HT4(a) receptor.
It was also of particular interest to check whether the elec-
trophysiological assay is suitable for measuring basal constitu-
tive activity of the receptor. To test for that, we compared the
first currents recorded after the establishing whole cell config-
uration, but before stimulation with serotonin in the cell ex-
pressing the HvCNG channel alone or with co-expressed
5-HT4(a) and Gs. For the Cys
3863 Ser mutant as well as for the
acylation-deficient receptor (Cys3283 Ser/Cys3293 Ser/Cys386
3 Ser), we obtained no significant differences in the basal,
agonist-independent channel stimulation as compared with the
receptor wild type (Fig. 4). In contrast, the mutant Cys328 3
Ser/Cys329 3 Ser considerably increased the level of agonist-
independent channel stimulation (Fig. 4, C328/329-S). The
activation constant  calculated for the wild type was decreased
from 665  114 ms (control) to 272  47 ms (5-HT stimulation;
n  4). However, in the case of the Cys3283 Ser/Cys3293 Ser
mutant,  value was changed from 423  100 ms (control) to
243  40 ms (5-HT stimulation, n  3).
Taken together, these data demonstrate that using the sen-
sitive HvCNG ion channel as a cAMP sensor provides a new
functional method to monitor receptor-effector interactions. In
addition, electrophysiological measurement of agonist-inde-
pendent channel activation confirmed the involvement of a
proximal acylation site (Cys328/Cys329) of the 5-HT4(a) receptor
in the regulation of constitutive receptor activity.
Mutations of Palmitoylated Cysteine Residues Resulted in
Different Constitutive Activities of the 5-HT4(a) Receptor after
Expression in COS-7 Cells—The experiments with insect cells
demonstrated the possible involvement of palmitoylation in
regulation of basal constitutive activity (Figs. 3 and 4). There-
fore, we next tested agonist-independent activation of acyla-
tion-deficient 5-HT4(a) mutants in the mammalian cell system.
The cDNA encoding for wild type and mutant receptors was
cloned in a pTracer plasmid (Invitrogen), and the ability of
these proteins to modulate an intracellular level of cAMP was
examined in transfected COS-7 cells as the function of receptor
density. As shown in Fig. 5A and as reported previously (28,
29), the native 5-HT4(a) receptor expressed in these cells pos-
sess a high basal constitutive activity as compared with mock-
transfected cells. The constitutive activity of the wild type
5-HT4(a) receptor was almost linearly proportional to the recep-
tor density (Fig. 5A). When the basal activity of the Cys328 3
Ser/Cys3293 Ser mutant was analyzed, we found more than a
2.5-fold increase in the agonist-independent cAMP production
as compared with the wild type receptor. In contrast, agonist-
independent cAMP production for the Cys386 3 Ser as well as
for the Cys328 3 Ser/Cys329 3 Ser/Cys386 3 Ser mutants
expressed at the same receptor density was quite similar to the
wild type (Fig. 5A). The inset in Fig. 5A also illustrates that the
high basal activity obtained for the Cys3283 Ser/Cys3293 Ser
mutant leads to a decrease in relative efficacy of 5-HT (106 M)
to stimulate over basal constitutive activity. Also notable is the
fact that the 5-HT-mediated maximal response was slightly
reduced in acylation-deficient mutants. Based on the two-state
model (29), we also calculated the constant J, i.e. the equilib-
rium constant denoting the ratio of the receptor in the inactive
versus active state (J [R]/[R*]) for the wild type and mutants.
We found that [R*] was 16  4.2, 31.5  3.7, 13.1  2.8, and
17.6  3.1% for the wild type, Cys328 3 Ser/Cys329 3 Ser,
Cys386 3 Ser, and Cys328 3 Ser/Cys329 3 Ser/Cys386 3 Ser,
respectively.
Although our experiments were performed with dialyzed
serum, it was important to check whether some contamination
by 5-HT could be responsible for the observed intrinsic activity.
Therefore, we used highly selective 5-HT4(a) receptor agonists/
antagonists. Whereas the neutral antagonist ML 10375 did not
have any effect on the 5-HT-induced constitutive receptor ac-
tivity, the inverse agonist the SB 207266 reduced the basal
constitutive activity of all receptors (Fig. 5B). Both substances
used in Fig. 5B were highly potent in inhibiting the 5-HT-
induced cAMP production (data not shown). When these antag-
onists were used together, the neutral antagonist reversed the
effect of the inverse agonist, indicating that both drugs acted on
the same 5-HT4 receptor site (data not shown). Thus, these
experiments indicated that the observed constitutive activity
was not because of 5-HT contamination.
Pharmacological Characterization of Wild type and Mutated
5-HT4(a) Receptors—Next we compared the pharmacological
profiles of wild type and mutated 5-HT4(a) receptors. The ex-
tended ternary complex (43) as well as cubic ternary complex
(44) introduced for the modeling of the GPCR isomerization
from R to R* and for their interaction with G-proteins, indi-
cated that the observed affinity of the agonist increased as a
function of the isomerization allosteric constant J (J 
[R]/[R*]). Indeed, we observed that the affinity of 5-HT for the
mutated receptor (Cys328 3 Ser/Cys329 3 Ser) increased by
almost a factor of 10 when compared with the wild type and
other mutants expressed at similar densities (Fig. 6, Table I).
5-HT binding was measured by competition with the high
affinity antagonist [3H]GR 113808 in the membrane prepara-
tion of transfected COS-7 cells. All displacement curves were
monophasic. As shown in Table I, the affinity of [3H]GR 113808
for wild type 5-HT4(a) receptors (KD  0.12 nM), was similar to
that obtained for the Cys386 3 Ser (KD  0.13 nM) and Cys
328
3 Ser/Cys329 3 Ser/Cys386 3 Ser (KD  0.13 nM) mutants.
However, it was different from that of the Cys3283 Ser/Cys329
3 Ser (KD  0.25 nM) mutant. Competition binding analysis
also demonstrated that the Ki value for 5-HT obtained with the
Cys328 3 Ser/Cys329 3 Ser mutant was 10-fold lower when
compared with the wild type receptor and other mutants (Table
I). We also found that the EC50 of 5-HT to stimulate cAMP was
about 5 times lower in mutant Cys3283 Ser/Cys3293 Ser than
in other mutants or in the wild type (Fig. 6B, Table I).
Intracellular Distribution of Wild type and Mutant Receptors
Expressed in COS-7 Cells—To examine the intracellular localiza-
tion of the wild type and mutated 5-HT4(a) receptors, the genes
encoding for the appropriate proteins were cloned in a pTracer
plasmid and expressed in COS-7 cells. Because this vector also
contains the green fluorescent protein gene under control of sep-
arate promotor, the cells expressing recombinant receptors may
be visualized easily by green fluorescence. To monitor expression
and intracellular distribution of receptors, transfected COS-7
cells were subjected to immunofluorescence. As seen in Fig. 7,
there were no apparent differences in the immunostaining be-
tween wild type and mutated receptors. This suggests that
palmitoylation did not critically contribute to the intracellular
distribution of the recombinant 5-HT4(a) receptors.
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DISCUSSION
From analysis of the primary structure of acylated GPCRs, it
is known that palmitoylation occurs exclusively on cysteine
residues located at the COOH-terminal juxta-membrane por-
tion of the receptors (40, 45). The 5-HT4(a) receptor possesses
four cysteine residues within its COOH-terminal cytoplasmic
domain, Cys328/Cys329, Cys346, and Cys386. In the present study
we identify cysteine residues 328/329 and cysteine 386 as po-
tential palmitoylation sites of the 5-HT4(a) receptor. Our find-
ing that conserved cysteine residues 328/329 are modified with
palmitic acid, whereas cysteine 346 located further away from
the membrane is not acylated, is consistent with a general view
of the location of GPCR’s palmitoylation sites. Quite contrary,
the existence of an additional palmitoylated cysteine 386 posi-
tioned 70 amino acids away from the plasma membrane face
and close to the COOH-terminal end of the 5-HT4(a) receptor
(Fig. 1) was surprising. Several palmitoylated GPCRs (e.g. va-
sopressin V2, endothelin B, luteinizing hormone/human chori-
onic gonadotropin, and 2-adrenergic receptors) also possess
multiple cysteine residues within their cytoplasmic COOH-
terminal domains. In these receptors, however, only cysteine
residues in positions up to 14 amino acids from the membrane
border toward the cytoplasmic tail have been shown to serve as
acylation sites (16, 46–48). No experimental evidence has been
provided so far for the fatty acid transfer to the cysteine resi-
dues located more distantly. Thus, the 5-HT4(a) receptor repre-
sents the first case of palmitoylated receptors with the novel
acylation site located close to its COOH terminus.
This finding could have additional implications in the con-
text of the great number of 5-HT4 receptor splicing variants
differing only in their C termini sequences after residue Leu358
(27, 28). Among these different isoforms, only the 5-HT4(a)
receptor possesses a Cys386 both localized close to the COOH
terminus and susceptible to palmitoylation. To date, nothing
has clearly been reported on the specific role or localization of
the different receptor splicing variants, except that isoforms of
5-HT4 receptor differ in their basal constitutive activity (28,
29). The present study, therefore, points out for the first time
the structural divergence between different 5-HT4 receptor
isoforms, which could posses some functional importance, like
differential regulation of basal and agonist-promoted receptor
activities.
For a number of peripheral membrane proteins involved in
signal transduction (e.g. p21ras,  subunits of heterotrimeric
G-protein, and endothelial nitric-oxide synthase), palmitoyla-
tion has been reported to be a regulated process (reviewed in
Ref. 10). In addition, several GPCRs, including 2-adrenergic
and dopamine D1 receptors, undergo a regulated turnover of
palmitate upon receptor stimulation (13, 15, 49). For the
5-HT4(a) receptor, we have also demonstrated that agonist
stimulation enhanced the palmitate exchange on this polypep-
tide (31). Given that the 5-HT4(a) receptor is palmitoylated at
two different sites within its COOH-terminal cytoplasmic do-
main (Fig. 1), it could be speculated that acylation of both sites
may be modulated by the agonist. The results of the presentFIG. 5. Mutations of palmitoylated cysteine residues of the
5-HT4(a) receptor differently affect the agonist-independent
cAMP production. A, COS-7 cells expressing different receptor
amounts (from 200 to 10,000 fmol/mg protein) were assayed for basal
cAMP production. The percentage of conversion of [3H]ATP to
[3H]cAMP in mock-transfected COS-7 cells was 0.105  0.014 (control).
Levels of cAMP accumulation were measured after 15 min of incuba-
tion and shown as a percentage of the control. Each point represents
the means  S.E. from four independent experiments performed in
triplicate. Inset, basal and maximal cAMP accumulation in response to
106 M 5-HT measured in COS-7 cells expressing between 1527 and
1780 fmol of receptor/mg of protein. The percentage conversion of
[3H]ATP to [3H]cAMP in mock-transfected COS-7 cells was 0.128 
0.011 (control). Each value represents the means  S.E. from four
independent experiments performed in triplicate. A statistically signif-
icant increase from values obtained without agonist with Cys328
3 Ser/Cys3293 Ser mutant is noted (*, p	 0.05). B, effect of two potent
5-HT4(a) receptor drugs: an inverse 5-HT4 receptor agonist SB 207266
and a neutral antagonist ML10375 on agonist-independent cAMP pro-
duction in COS-7 cells expressing either wild type or mutated 5-HT4(a)
receptors. The receptor surface density was between 1800 and 2300
fmol/mg of protein. The percentage conversion of [3H]ATP to [3H]cAMP
in mock-transfected cells was 0.14  0.018 (control). The basal cAMP
formations in wild type and mutants Cys3283 Ser/Cys3293 Ser, Cys386
3 Ser, and Cys328 3 Ser/Cys329 3 Ser/Cys386 3 Ser were 700  67,
1890 59, 780 65, and 930 80% of control, respectively. Each value
is the means  S.E. from three independent experiments performed in
triplicate.
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experiments support this view, demonstrating that palmitoy-
lation of the each individual acylation site is a dynamic process
(Fig. 2). Although the detailed mechanism involved in the reg-
ulation of palmitoylation/depalmitoylation cycles of individual
cysteines on the 5-HT4(a) receptor is still unknown, our results
indicate that the biological activation of the 5-HT4(a) receptor
enhances the palmitate exchange on both acylation sites
(Cys328/Cys329 and Cys386).
Functional analyses of mutant GPCRs lacking the acylation
site have failed to reveal a common functional role for receptor
palmitoylation. Moreover, mutagenesis of the palmitoylated
cysteine residues is often associated with different, sometimes
opposite effects on the functional receptor activities. Therefore,
by using acylation-deficient mutants of the 5-HT4(a) receptor,
we analyzed the possible role of dynamic palmitoylation in
different receptor properties, including coupling with hetero-
trimeric G-proteins, ligand-binding efficiency, intracellular dis-
tribution, modulation of downstream signal cascades, as well
as modulation of basal constitutive receptor activity. Evalua-
tion of agonist-promoted binding of [35S]GTPS with G-pro-
teins belonging to different families revealed that the recombi-
nant 5-HT4(a) receptor communicates with Gs but not with
Gi, Gq, or G12 subunits (Fig. 3). Additional assays, includ-
ing agonist-promoted cAMP production (Fig. 6) and activation
of cAMP-gated ion channels (Fig. 4), also confirmed that the
5-HT4(a) receptor operates through Gs. This observation is in
line with the current notion that native as well as heterolo-
gously expressed 5-HT4 receptors couple positively to adenylate
cyclase catalyzing cAMP production (37, 50).
Analysis of acylation-deficient 5-HT4(a) mutants revealed
that non-palmitoylated receptors are indistinguishable from
the wild type in their ability to interact with Gs (Fig. 3), to
activate cyclic nucleotide-sensitive cation-channels (Fig. 4),
and to stimulate adenylyl cyclase activity (Fig. 6) after agonist
stimulation. The lack of any effect of palmitoylation on the
coupling of the 5-HT4(a) receptor with G-proteins and on the
downstream effectors, parallels recent reports on palmitoyla-
tion of the 2-adrenergic receptor (2AR). The 2AR couples to
both Gs as well as to Gi (51), and mutation of cysteine 442,
resulting in non-palmitoylated receptor, has no effect on cou-
pling with either class of G-proteins (52). This differs from the
features reported for rhodopsin, 2AR, as well as for endothelin
types A and B (ETA and ETB) receptors. Recent works on
rhodopsin indicate that chemical depalmitoylation enhances
light-dependent GTPase activity of Gt and strongly decreases
the light-independent activity of opsin-atr (17, 53). Similarly,
functional characterization of non-palmitoylated 2AR and the
ETB receptor revealed that palmitoylation is essential for ago-
nist-stimulated coupling to Gs and to both Gq and Gi proteins,
respectively (45, 54). Analysis of the non-palmitoylated ETA
receptor mutant demonstrated that ligand-induced stimulation
of Gs was unaffected by the lack of palmitoylation, whereas
signaling through Gq was abolished (55). These opposing find-
ings suggest that palmitoylated cysteine residues may play
differing roles at different receptor-G-protein interfaces. This
may be because of the different subunit composition of Gs, Gq,
Gt, and Gi/o or, alternatively, to the differing receptor struc-
tures presented to the appropriate G-proteins.
Immunofluorescence analysis of transfected COS-7 cells
(Fig. 7) suggested that palmitoylation was also not critically
involved in intracellular distribution of the wild type 5-HT4(a)
receptor. The immunofluorescence assay used, however, is not
quantitative, and the intracellular traffic of the receptor mol-
ecule as well as fine tuning of receptor localization could not be
assessed. Therefore, it is still an open question whether the
intracellular trafficking of the 5-HT4(a) receptor to the “correct”
site within the plasma membrane may be actively regulated by
the receptor palmitoylation. In a search for the possible role of
the 5-HT4(a) receptor palmitoylation in a defined subcellular
distribution, careful analysis of intracellular transport of acy-
lation-deficient mutants should be done.
The most distinct finding of the present study was the ob-
servation that palmitoylation modulates the agonist-indepen-
dent constitutive 5-HT4(a) receptor activity. Spontaneous or
constitutive GPCR activity has been described convincingly for
10 years in the pioneering work of Costa and Lefkowitz (56, 57).
Now it is well established that GPCRs can reach their active
state even in the absence of agonist, as a result of a natural
shift in the equilibrium between their inactive and active con-
FIG. 6. Competition binding and 5-HT-induced cAMP forma-
tion in COS-7 cells expressing 5-HT4(a) receptor wt or acylation-
deficient mutants. A, competition binding of 5-HT for [3H]GR 113808
in membranes derived from COS-7 cells expressing comparable
amounts of wild type and mutated receptors (receptor surface densities
between 827 and 1180 fmol/mg). Data points represent the means 
S.E. from at least four independent experiments. B, intracellular cAMP
level was measured at increasing concentrations of 5-HT in transfected
COS-7 cells. The maximal increase in the ligand-dependent activity
differs between receptors. The basal and 5-HT maximal adenylyl cy-
clase stimulation values are shown as percentage of control. Data points
represent the means  S.E. from four independent experiments per-
formed in triplicate.
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formations (58). The capacity of a native receptor to spontane-
ously isomerize from an inactive form (R) to an active form (R*)
is certainly a very important pharmacological characteristic
because this may explain part of its physiological and possible
pathological behavior, as well as the effect of drugs classified as
inverse agonists (able to reverse the isomerization because of
their higher affinity for R than for R*) on the receptor. Al-
though the agonist-independent signaling has been observed
for a wide variety of GPCRs (in particular after their overexpres-
sion in heterologous cells), molecular constrains involved in the
regulation of receptor constitutive activity remain poorly under-
stood. There are some data to indicate that specific sequences
within the third intracellular loop i3, as well as composition of
the COOH-terminal tail of GPCRs, may be essential for the
isomerization of receptors from the R to the R* form (58).
In the present study, we demonstrate that mutation of con-
served cysteine residues 328/329 located at the COOH-termi-
nal tail of the 5-HT4(a) receptor elevates the receptor basal
constitutive activity. Binding of [35S]GTP S to Gs as well as
the basal activation of the HvCNG channel were significantly
increased after mutation of these cysteine residues (Figs. 3 and
4). Expression of the Cys328 3 Ser/Cys329 3 Ser mutant in
COS-7 cells resulted in an2.5-fold higher basal level of cAMP
formation when compared with the wild type receptor (Fig. 5).
In addition, this mutant possesses a significantly lowered li-
gand-binding affinity (Table I) and its EC50 value was shifted
from 3 nM (wild type and other mutants) to 0.6 nM 5-HT (Table
I, Fig. 6). In contrast, mutation of Cys386, which is also sub-
jected to palmitoylation (Figs. 1 and 2) had no effect on the
agonist-independent receptor activation. It is interesting to
note that simultaneous substitution of Cys328/Cys329 and
FIG. 7. Role of palmitoylation for
the intracellular 5-HT4(a) receptor
distribution. COS-7 cells were trans-
fected either with wild type or mutant
5-HT4(a) receptor cDNAs. 48 h after trans-
fection, cells were fixed, permeabilized,
and then subjected to immunofluores-
cence analysis with an antibody AS9459
raised against the COOH terminus of
5-HT4(a) receptor. After incubation with
the fluorescent second antibodies, cells
were subjected to the confocal microscopy
with appropriated filters set at magnifi-
cation of 630.
FIG. 8. Proposed mechanism for the modulation of 5-HT4(a)
receptor constitutive activity by palmitoylation. The seventh
transmembrane domain as well as carboxyl-terminal cytoplasmic tail of
the 5-HT4(a) receptor are schematically shown. Depending on the num-
ber of cysteine residues modified, palmitoylation could result in the
formation of two (a), one small (b), one large (c), or no (d) intracellular
loops. In the present model, every conformation could be changed to one
of the remaining three forms by basal or agonist-promoted palmitate
turnover. Percentage of receptor population in the R* form was calcu-
lated based on the two-state model as described by Claeysen et al. (29).
TABLE I
Results of binding experiments and cAMP production for the wild-type and acylation-deficient 5-HT4(a) receptors
Wild type (WT) and mutant receptors were transiently transfected in COS-7 cells and used for saturation (KD values) and competition (Ki values)
binding analyses. [3H]GR 113808 was used as a selective antagonist. EC50 values refer to the agonist concentrations yielding 50% of the maximal
activation. Data are expressed as means  S.E. of at least four independent experiments. Significantly different values obtained for the Cys3283
Ser/Cys329 3 Ser mutant as compared with the wt and mutant receptors Cys386 3 Ser and Cys328 3 Ser/Cys329 3 Ser/Cys386 3 Ser are noted
(*, p 	 0.01).
WT and mutated 5-HT4(a) receptors
5-HT4(a) receptor binding sites




5-HT; Ki  S.E. Agonist: 5-HT; EC50  S.E.
nM nM nM
WT 0.12  0.03 86.7  8.8 3  0.42
Cys328 3 Ser/Cys329 3 Ser 0.25*  0.07 7.8*  0.2 0.6*  0.15
Cys386 3 Ser 0.13  0.04 64  7.6 3  0.28
Cys328 3 Ser/Cys329 3 Ser/Cys386 3 Ser 0.13  0.02 102  9 3  0.35
Agonist-independent Activation of 5-HT4(a) Receptor2544
Cys386, which completely abolishes palmitoylation of the
5-HT4(a) receptor, reverses the high constitutive activity ob-
tained for the Cys328 3 Ser/Cys329 3 Ser mutant to a level
obtained for the wild type.
What could be a possible scenario in which the different
palmitoylation states of the 5-HT4(a) receptor differently mod-
ulate its constitutive activity? It has been proposed that palmi-
toylation of GPCRs may provide a lipophilic membrane anchor
to create an additional fourth intracellular loop in the carboxyl-
terminal region of the receptor (9, 59). More recently, direct
evidence for this has been obtained for rhodopsin (60, 61). The
5-HT4(a) receptor possesses two different acylation sites at its
COOH-terminal domain (Fig. 1). Therefore, “complete” palmi-
toylation of the 5-HT4(a) receptor may result in the formation of
two additional intracellular loops i4 and i5 (Fig. 8a). Function-
ally, this conformation could be critical for determining the
basal level of agonist-independent receptor activation. When
cysteine residues 328/329 become depalmitoylated (by basal or
agonist-promoted palmitate turnover), a single large intracel-
lular loop could be generated instead of i4 and i5 loops (Fig. 8c).
From a functional point of view, such a change in the confor-
mation could lead to the significant increase of the receptor’s
constitutive activity by shifting R3 R* equilibrium toward the
R* state. Based on the two-state model, we calculated that
about 32% of the total Cys328 3 Ser/Cys329 3 Ser mutant
receptor population was in the activated R* state. For the wild
type 5-HT4(a), this value was only 16% (29). Subsequent de-
palmitoylation of the cysteine residue 386 destroys the large
activating loop and therefore reduces the receptor activity to
the wild type level (Fig. 8d). Generally, our model proposes that
palmitoylation of the 5-HT4(a) receptor is directly involved in
isomerization of the receptor from R to R* by dictating confor-
mation of its flexible cytoplasmic loops involved either in the
receptor/G-protein recognition process or in G-protein binding
and/or receptor-mediated G-protein activation. Taken together
with the fact that palmitoylation of the 5-HT4(a) receptor is a
dynamic process (Ref. 31, Fig. 2), this model could also explain
the higher constitutive activity reported for the native 5-HT4(a)
receptor as compared with other GPCRs (28, 30). Indeed, ex-
istence of palmitate turnover implies that at any given point
different populations of the palmitoylated and non-palmitoy-
lated 5-HT4(a) receptors, including the form with a large acti-
vating loop (Fig. 8c), are present in the cell and therefore
actively contribute to the agonist-independent receptor activ-
ity. Moreover, it can be proposed that agonist stimulation, by
promoting depalmitoylation of the receptor, regulates mem-
brane attachment of the carboxyl tail, providing a formation of
the large activating loop. The detailed mechanism involved in
the regulation of different palmitoylation states of the 5-HT4(a)
receptor is still unclear. One possibility is that palmitoylation
and/or depalmitoylation enzymes may directly regulate produc-
tion of different acylation states of the receptor. Alternatively,
other intracellular proteins, like the Homer protein for the
metabotropic glutamate receptors (62), could be involved in the
controlling process.
In conclusion, we have demonstrated that the mouse
5-HT4(a) receptor contains two potential palmitoylation sites
(Cys328/Cys329 and Cys386) located in the carboxyl-terminal
domain of the receptor. These two sites are palmitoylated in-
dependently of each other in an agonist-dependent manner.
Palmitoylation does not contribute to the coupling with Gs nor
to the intracellular distribution. We also revealed the critical
role of palmitoylation in the modulation of the receptor’s con-
stitutive activity and propose that dynamic palmitoylation of
two different acylation sites within the COOH-terminal tail of
the 5-HT4(a) receptor represents a novel mechanism regulating
both agonist-promoted as well as constitutive receptor
activities.
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